The Montreal-based company is at risk from potential tariffs from President Donald Trump and Canada’s government that could adversely affect its financial results.
Located at its global headquarters in Craigavon, the new 100,000-square-foot facility augments Almac’s capabilities in the manufacture of oral dose treatments.
The investment supports the construction of an R&D and manufacturing hub to advance Entos’ Fusogenix PLV drug delivery platform and expand Canadian biomanufacturing capacity.
